Tirzepatide trial SURMOUNT-3 assesses weight loss maintenance post-intensive lifestyle program in obesity.

Maintaining weight loss is a significant challenge for individuals with obesity or overweight, often leading to weight regain despite initial success. While intensive lifestyle programs can induce substantial initial weight reduction, sustaining these benefits long-term remains difficult due to complex physiological adaptations that promote weight regain. Current pharmacotherapies, including GLP-1 receptor agonists and GIP receptor agonists, have demonstrated remarkable efficacy for inducing weight loss, but their role in the crucial maintenance phase, particularly after a structured lifestyle intervention, requires further investigation. Understanding how agents like tirzepatide can support sustained weight management is critical to improving long-term health outcomes and addressing the global burden of obesity-related comorbidities.

The SURMOUNT-3 trial (NCT04657016) is a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of tirzepatide once weekly for weight loss maintenance. Participants included adults without Type 2 Diabetes who have obesity or are overweight with weight-related comorbidities. The study design involved an initial intensive lifestyle program phase, after which participants were randomized to receive either tirzepatide or placebo. The primary endpoint focused on assessing the ability of tirzepatide to maintain or further reduce body weight compared to placebo following the initial weight loss achieved through lifestyle interventions. This rigorous design aims to isolate the specific contribution of tirzepatide to long-term weight management.

The provided research record does not include specific findings or results from the SURMOUNT-3 trial. Therefore, no data, percentages, p-values, or fold-changes can be reported at this time. The trial's objective is to determine if tirzepatide can effectively maintain weight loss achieved through an intensive lifestyle program in adults with obesity or overweight, and to assess its safety profile in this context. Future publications from this trial are expected to detail outcomes related to body weight change, body composition, and metabolic parameters.